Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Zhangzhou Pientzehuang Pharmaceutical., Ltd, together with its subsidiaries, manufactures and distributes pharmaceuticals and cosmetics in China and internationally. It offers Chinese medicines in various forms, including capsules, tablets, pills, syrups, and ointments, as well as health care food and functional drinks, special efficacy cosmetics, and household chemicals under the Pien Tze Huang … Read more
Zhangzhou Pientzehuang Pharmaceutical Co Ltd (600436) - Total Assets
Latest total assets as of September 2025: CN¥17.48 Billion CNY
Based on the latest financial reports, Zhangzhou Pientzehuang Pharmaceutical Co Ltd (600436) holds total assets worth CN¥17.48 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Zhangzhou Pientzehuang Pharmaceutical Co Ltd - Total Assets Trend (2000–2024)
This chart illustrates how Zhangzhou Pientzehuang Pharmaceutical Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Zhangzhou Pientzehuang Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Zhangzhou Pientzehuang Pharmaceutical Co Ltd's total assets of CN¥17.48 Billion consist of 64.6% current assets and 35.4% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 8.5% |
| Accounts Receivable | CN¥958.38 Million | 5.5% |
| Inventory | CN¥4.97 Billion | 28.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥273.10 Million | 1.6% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2000–2024)
This chart illustrates how Zhangzhou Pientzehuang Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zhangzhou Pientzehuang Pharmaceutical Co Ltd's current assets represent 64.6% of total assets in 2024, a decrease from 76.0% in 2000.
- Cash Position: Cash and equivalents constituted 8.5% of total assets in 2024, up from 2.3% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2000.
- Asset Diversification: The largest asset category is inventory at 28.3% of total assets.
Zhangzhou Pientzehuang Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Zhangzhou Pientzehuang Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Novartis AG
PINK:NVSEF
|
USA | $115.49 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $208.73 Billion |
|
AbbVie Inc
NYSE:ABBV
|
USA | $133.96 Billion |
|
Biogen Inc
NASDAQ:BIIB
|
USA | $29.44 Billion |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705
|
China | CN¥3.03 Billion |
|
Hunan Jingfeng Pharmaceutical
SHE:000908
|
China | CN¥877.99 Million |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.58 Billion |
Zhangzhou Pientzehuang Pharmaceutical Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Zhangzhou Pientzehuang Pharmaceutical Co Ltd generates 0.62x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Zhangzhou Pientzehuang Pharmaceutical Co Ltd generates $ 16.97 in net profit.
Zhangzhou Pientzehuang Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.00 | 5.12 | 4.61 |
| Quick Ratio | 2.12 | 3.64 | 3.39 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥8.56 Billion | CN¥ 12.75 Billion | CN¥ 6.50 Billion |
Zhangzhou Pientzehuang Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Zhangzhou Pientzehuang Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.98 |
| Latest Market Cap to Assets Ratio | 0.30 |
| Asset Growth Rate (YoY) | 2.7% |
| Total Assets | CN¥17.54 Billion |
| Market Capitalization | $5.34 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Zhangzhou Pientzehuang Pharmaceutical Co Ltd's assets below their book value (0.30 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Zhangzhou Pientzehuang Pharmaceutical Co Ltd's assets grew by 2.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Zhangzhou Pientzehuang Pharmaceutical Co Ltd (2000–2024)
The table below shows the annual total assets of Zhangzhou Pientzehuang Pharmaceutical Co Ltd from 2000 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥17.54 Billion | +2.69% |
| 2023-12-31 | CN¥17.08 Billion | +16.96% |
| 2022-12-31 | CN¥14.60 Billion | +16.87% |
| 2021-12-31 | CN¥12.50 Billion | +22.44% |
| 2020-12-31 | CN¥10.21 Billion | +15.83% |
| 2019-12-31 | CN¥8.81 Billion | +32.34% |
| 2018-12-31 | CN¥6.66 Billion | +17.87% |
| 2017-12-31 | CN¥5.65 Billion | +12.12% |
| 2016-12-31 | CN¥5.04 Billion | +24.24% |
| 2015-12-31 | CN¥4.05 Billion | +11.10% |
| 2014-12-31 | CN¥3.65 Billion | +11.98% |
| 2013-12-31 | CN¥3.26 Billion | +46.11% |
| 2012-12-31 | CN¥2.23 Billion | +42.21% |
| 2011-12-31 | CN¥1.57 Billion | +8.42% |
| 2010-12-31 | CN¥1.45 Billion | +12.63% |
| 2009-12-31 | CN¥1.28 Billion | +19.99% |
| 2008-12-31 | CN¥1.07 Billion | +10.27% |
| 2007-12-31 | CN¥970.88 Million | +32.88% |
| 2006-12-31 | CN¥730.62 Million | +5.33% |
| 2005-12-31 | CN¥693.63 Million | +24.13% |
| 2004-12-31 | CN¥558.77 Million | -6.09% |
| 2003-12-31 | CN¥594.99 Million | +82.63% |
| 2002-12-31 | CN¥325.79 Million | +20.50% |
| 2001-12-31 | CN¥270.36 Million | +4.52% |
| 2000-12-31 | CN¥258.68 Million | -- |